Clinical Trials Browser

Completed × INDUSTRY × Jaundice × Clear all

Endocrine Gland Neoplasms, Jaundice, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms

NCT02921828 2022-07-05

A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg

Sleepiness, Arrhythmias, Cardiac, Confusion, Consciousness Disorders, Dizziness, Fatigue, Heart Failure, Hypersensitivity, Infections, Jaundice, Liver Diseases, Multiple Myeloma, Peripheral Nervous System Diseases, Thromboembolism, Tumor Lysis Syndrome, Lung Diseases, Interstitial, Acute Kidney Injury, Teratogenesis

NCT02098239 2014-03-27

Single Centre Study to Determine the Antibody Response to G17DT in Patients With Advanced Pancreatic Cancer.

Phase 2 Completed

41 enrolled

Gastrointestinal

Jaundice, Pancreatic Neoplasms

NCT00196105 2011-10-03

Malignant Obstruction ZILVER Against Routine Therapy (MOZART I)

Phase NA Completed

241 enrolled 15 charts

Gastrointestinal

Biliary Tract Neoplasms, Jaundice, Pancreatic Neoplasms, Jaundice, Obstructive

Clinical Trials

GAMMA

A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg

Single Centre Study to Determine the Antibody Response to G17DT in Patients With Advanced Pancreatic Cancer.

Malignant Obstruction ZILVER Against Routine Therapy (MOZART I)